Favorable Government Support Fuels Germany's Biotech Innovation and Commercialization: Market to Surpass USD 94 Billion by 2034 Led by QIAGEN, Thermo Fisher Scientific, Illumina and Roche
Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Germany Biotechnology Market Report and Forecast 2025-2034" has been added to ResearchAndMarkets.com's offering.The Germany biotechnology market was valued at USD 35.30 Billion in 2024, bolstered by robust public and private investment in biotech innovation, alongside significant R&D endeavors supported by established academic and research institutions. The market is expected to grow at a CAGR of 10.30% during 2025-2034, potentially reaching USD 94.09 Billion by 2034.
Government initiatives and funding play a critical role in accelerating the development and commercialization of advanced biotechnological solutions, contributing to market expansion. This growth is also underpinned by strong infrastructure, substantial R&D capabilities, and a skilled workforce. The increasing adoption of precision medicine and biopharmaceuticals is anticipated to further drive market growth in the forecast period.
Increasing Prevalence of Chronic Diseases
The market's growth is heavily influenced by the rising incidence of chronic and degenerative diseases. According to WHO data from 2021, conditions such as ischemic heart disease, Alzheimer's disease, stroke, various cancers, COPD, and kidney disorders impose a significant health burden, intensifying demand for innovative diagnostics, targeted therapies, and precision medicine. This drives forward the biotechnology sector, bolstered by increased research and development investments from both public and private sectors.
Germany Biotechnology Market Trends
Key trends include rising investments and the advent of cutting-edge, sustainable technologies. Investment confidence continues to grow, evidenced by a 78% increase in funding for German biotech firms, reaching EUR 1.917 billion in 2024, according to BIO Deutschland and EY. This capital influx is set to enhance market growth and technological progress.
Additionally, innovative, eco-friendly food technologies are driving demand. In March 2024, the launch of Kynda's zero-waste mycelium-based food product in Germany highlighted a move towards sustainable consumer solutions, anticipating an increase in the market's growth and the adoption of sustainable biotech products.
Germany Biotechnology Market Segmentation
The market analysis includes segments such as:
Product Type: Instruments, Reagents, Software and Services, Others
Technology: Nanobiotechnology, Tissue Engineering, DNA Sequencing, Cell-based Assays, Fermentation, PCR Technology, Chromatography, Others
Application: Health, Food & Agriculture, Natural Resources & Environment, Industrial Processing, Bioinformatics, Others
Germany Biotechnology Market Share: DNA Sequencing's Impact
The biotechnology market in Germany is diversified across various technologies, with DNA sequencing anticipated to lead. Innovations like Merck's Aptegra platform, which integrates multiple assays into one, significantly reduce testing times and costs, driving DNA sequencing's important role in the market's future growth.
Leading Players in the Germany Biotechnology Market
The major market players include:
QIAGEN N.V: Expanded its portfolio by acquiring Genoox, enhancing AI-driven genetic data interpretation for clinical decision-making.
Thermo Fisher Scientific, Inc: Introduced sustainable centrifuges in Germany, boosting energy efficiency in bioprocessing.
Illumina Inc: Partnered with Ovation.io to launch an extensive clinical multiomic dataset, propelling advancements in metabolic disease therapies.
F. Hoffman-La Roche Ltd: Gained FDA clearance for a dual mRNA probe assay improving B-cell lymphoma diagnostics.
Other key companies include Evotec SE, Bio-Rad Laboratories, Agilent Technologies, and BioNTech SE.
Key Questions Answered
What was the Germany biotechnology market value in 2024?
What is the forecast for 2025-2034?
What drives demand in the market?
How has the market performed historically, and future expectations?
What are the major trends and challenges?
Which product, technology, and application segments are expected to dominate?
Who are the key players?
Key Attributes
Report Attribute
Details
No. of Pages
250
Forecast Period
2025-2034
Estimated Market Value (USD) in 2025
$35.3 Billion
Forecasted Market Value (USD) by 2034
$94.09 Billion
Compound Annual Growth Rate
10.3%
Regions Covered
Germany
Key Topics Covered
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Biotechnology Market Overview
3.1 Europe Biotechnology Market
3.2 Germany Biotechnology Market
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Germany Biotechnology Market Landscape
5.1 Germany Biotechnology Market: Developers Landscape
5.2 Germany Biotechnology Market: Product Landscape
6 Germany Biotechnology Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.3 PESTEL Analysis
6.4 Porter's Five Forces Model
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Germany Biotechnology Market Segmentation (2018-2034)
7.1 By Product Type
7.2 By Technology
7.3 By Application
8 Regulatory Framework
9 Patent Analysis
10 Funding and Investment Analysis
11 Strategic Initiatives
12 Supplier Landscape
13 Germany Biotechnology Market - Distribution Model (Additional Insight)
14 Key Opinion Leaders (KOL) Insights (Additional Insight)
For more information about this report visit https://www.researchandmarkets.com/r/2dvmnn
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
German Biotechnology Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 minutes ago
- Associated Press
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
CARY, N.C., July 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ('Heron' or the 'Company'), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 11, 2025, at 4:30 p.m. ET to report second quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call. About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit Forward-looking Statements This news release contains 'forward-looking statements' as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira Duarte Executive Vice President, Chief Financial Officer Heron Therapeutics, Inc. [email protected] 858-251-4400 View original content to download multimedia: SOURCE Heron Therapeutics, Inc.
Yahoo
32 minutes ago
- Yahoo
Trump's New EU Trade Deal Labeled 'Bad News' By Economists As Dow Futures Spike Over 150 Points
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. President Donald Trump's latest trade deal with the European Union is drawing sharp criticism from several leading economists, who argue that it will disproportionately harm American consumers and businesses. What Happened: Following Trump's announcement on Sunday, economist Peter Schiff posted on X, with a blunt assessment of the deal, saying that 'Americans lose again.' Schiff says that under the new terms, 'we will pay 15% tariffs to buy most European goods, but 50% tariffs to buy European steel, aluminum, or copper, driving up material costs for many U.S industries.' Meanwhile, he notes, 'Europeans won't pay any tariffs on most U.S. imports.' Trending: Be part of the breakthrough that could replace plastic as we know it—University of Michigan economist Justin Wolfers echoed similar concerns, while highlighting the folly of imposing trade barriers. 'These trade deals are all underwhelming for one simple reason,' he says, and that's because trade barriers and tariffs have been tiny for decades. 'When tariffs are 1-2%, there's not much to gain from a trade war,' he says, while warning that a 15% tax on imports can, however, 'do a lot of harm to Americans.' Danish economist Lars Christensen pushed back against the narrative that this was a bad deal for the EU and a win for Trump. He says, 'the deal lower[s] EU tariffs,' which he believes is 'good news for European consumers,' while adding that it is bad for the U.S. economy. Christensen agrees with both Schiff and Wolfers, saying that 'the biggest losers are US consumers,' while comparing the deal to 'shooting yourself in the foot' for the U.S., which he says 'is never a victory.'Why It Matters: The announcement of the trade deal with the EU on Sunday brought an end to months of trade and tariff-related uncertainties with the U.S.'s biggest trading partner. Besides the 15% tariff on imports from the region, the EU will also be buying $750 billion worth of U.S. energy, while investing $600 billion in the United States. Additionally, nations in the bloc will be purchasing weapons from the U.S., although no amount was mentioned. Meanwhile, top officials from the U.S. and China are set to meet in Stockholm to address pressing trade issues, with Trump saying last week that 'We have the confines of a deal with China.' U.S. stock futures are up pre-market, following news of the trade deal over the weekend. The S&P 500 Futures are up 0.37%, trading at 6,449.00, and Nasdaq Futures at 23,538.25, up 0.50%, followed by Dow Futures, which rose over 150 points, up 0.33%, trading at 45,234.00, at the time of writing. Photo Courtesy: Savvapanf Photo on Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? This article Trump's New EU Trade Deal Labeled 'Bad News' By Economists As Dow Futures Spike Over 150 Points originally appeared on
Bloomberg
34 minutes ago
- Bloomberg
Taiwan Investors Turn to Europe as US Assets Lose their Allure
Taiwanese investors are reassessing their long-held preference for US-dollar assets, shifting their bets to Europe in the latest move by global investors away from the greenback. Taiwanese funds holding European assets have seen an influx of investments recently, pushing their combined value to NT$13.7 billion ($463 million) as of the end of June, the highest since 2019, according to data compiled by Bloomberg.
